DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

UPDATE: Raymond James On Abbott Laboratories Notes 'While we are a bit uncomfortable with the valuation, Abbott's growth profile (7-8% revenue, 12-15% EPS) is well above peers and with beatable estimates'

Benzinga · 01/23/2020 16:50